NDA 020692 · Glaxosmithkline
Serevent
Salmeterol Xinafoate · Inhalation
Last checked: Nov 19, 2026Latest source record: Jul 22, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Sep 19, 1997
Approved uses
5
Original approval plus efficacy supplements
Registered trials
369
122 Phase 3, 7 recruiting
FAERS reports
8,614
5,067 serious, 965 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. Data from a large placebo-controlled U.S. trial that compared the safety of salmeterol with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol (13 deaths out of 13,176 subjects treated for 28 weeks on salmeterol versus 3 deaths out of 13,179 subjects on placebo). Use of background ICS was not required in this study. When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone. Use of SEREVENT DISKUS for the treatment of...
What it is approved for
From the label in effect Oct 10, 2022.
SEREVENT DISKUS is a LABA indicated for: • Treatment of asthma in patients aged 4 years and older with an ICS. ( 1.1 ) • Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older. ( 1.2 ) • Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). ( 1.3 ) Important limitation of use: Not indicated for relief of acute bronchospasm. ( 1.1 , 1.3 ) 1.1 Treatment of Asthma SEREVENT DISKUS is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with an ICS in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death [see Warnings and Precautions ( 5.1 )] . Use of SEREVENT DISKUS for the treatment of asthma without concomitant use of an ICS is contraindicated [see Contraindications ( 4 )] . Use SEREVENT DISKUS only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ICS. Do not use SEREVENT DISKUS for patients whose asthma is adequately controlled on low- or medium-dose ICS. Pediatric and Adolescent Patients Available data from controlled clinical trials suggest that LABA as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent patients. For pediatric and adolescent patients with asthma who require addition of a LABA to an ICS, a fixed-dose combination product containing both an ICS and a LABA should ordinarily be used to ensure adherence with both drugs. In cases where use of a separate ICS and a LABA is clinically indicated, appropriate steps must be...
Mechanism: Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50% of the total beta-adrenoceptors. The precise function of these receptors has not been established, but their presence raises the possibility that even selective beta 2 -agonists may have cardiac effects....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 22, 2002 Supplement 16 · Efficacy LabelLetter
- Jun 29, 2000 Supplement 11 · Efficacy
- Sep 25, 1998 Supplement 2 · Efficacy ReviewLabelLetter
- Sep 25, 1998 Supplement 1 · Efficacy LabelReviewLetter
- Sep 19, 1997 Original approval · Type 3 - New Dosage Form ReviewOther Important Information from FDA
1 products under this application
- SEREVENT · SALMETEROL XINAFOATE EQ 0.05MG BASE/INH · POWDER, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Salmeterol Xinafoate" as an intervention, any sponsor and status, largest first.
GlaxoSmithKlineGSK (GSK)
NCT01475721 · 11,751 participants · Start Nov 18, 2011 · Primary completion Jun 23, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 4 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 808 sites in all
- Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00563381 · 7,376 participants · Start Jan 2008 · Primary completion Apr 2010
Drug: Tiotropium bromide; Salmeterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Feldbach, Austria; Feldkirch, Austria; Gänserndorf, Austria · 752 sites in all
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01462344 · 6,250 participants · Start Nov 17, 2011 · Primary completion Nov 1, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 2 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 530 sites in all
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268216 · 6,228 participants · Start Sep 2000 · Primary completion Nov 2005
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 459 sites in all
- QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01782326 · 3,362 participants · Start Jul 2013 · Primary completion Sep 2015
Drug: QVA149; Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Ciudad de Buenos Aires, Argentina; Buenos Aires, Argentina; Caba, Argentina · 499 sites in all
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
- A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT03034915 · 2,696 participants · Start Jun 16, 2017 · Primary completion Jun 18, 2018
Drug: UMEC/VI 62.5/25 mcg via ELLIPTA; UMEC 62.5 mcg via ELLIPTA and 3 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Phoenix, Arizona; Lincoln, California; Clearwater, Florida · 212 sites in all
- Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00975195 · 2,488 participants · Start Feb 2009 · Primary completion Jul 2013
Drug: tiotropium inhalation; salmeterol xinafoate and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Concord, Australia; Glebe, Australia; Westmead, Australia · 222 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,269
- drug ineffective1,232
- asthma919
- cough597
- headache474
- pneumonia413
- nausea403
- wheezing378
- dizziness368
- chest discomfort357
- fatigue355
- pharmaceutical product complaint318
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,507 |
| 2005 | 678 |
| 2006 | 562 |
| 2007 | 426 |
| 2008 | 446 |
| 2009 | 446 |
| 2010 | 433 |
| 2011 | 313 |
| 2012 | 283 |
| 2013 | 316 |
| 2014 | 328 |
| 2015 | 331 |
| 2016 | 370 |
| 2017 | 282 |
| 2018 | 292 |
| 2019 | 307 |
| 2020 | 252 |
| 2021 | 245 |
| 2022 | 178 |
| 2023 | 171 |
| 2024 | 231 |
| 2025 | 126 |
| 2026 | 88 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.
Li S, Feng K, Lee J, et al. · AAPS J 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS, Risebrough N, Li C, et al. · Respir Med 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma.
Weersink EJ, Douma RR, Postma DS, et al. · Am J Respir Crit Care Med 1997 · Clinical Trial, Randomized Controlled Trial
- Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.
Brogden RN, Faulds D · Drugs 1991 · Clinical Trial, Randomized Controlled Trial
- Inhaled long acting beta agonists for stable chronic asthma.
Walters EH, Walters JA, Gibson MD · Cochrane Database Syst Rev 2003 · Systematic Review
- Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Doull I, Price D, Thomas M, et al. · Curr Med Res Opin 2007 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.